Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Myocarditis IV: Nursing Management01:22

Myocarditis IV: Nursing Management

Myocarditis is an inflammatory condition of the myocardium requiring meticulous nursing management for optimal patient outcomes. Effective management begins with a thorough assessment of the patient's medical history, paying close attention to past infections, autoimmune disorders, travel history, and exposure to toxins or drugs. Recent viral infections and systemic diseases are particularly relevant due to their potential role in triggering myocarditis.Physical Examination and MonitoringThe...
Cytomegalovirus Disease01:27

Cytomegalovirus Disease

Cytomegalovirus (CMV) disease is caused by human cytomegalovirus, a double-stranded DNA virus of the Herpesviridae family. While primary CMV infection is often asymptomatic in immunocompetent individuals, the virus can cause severe disease in neonates and immunocompromised patients. CMV is the most common cause of congenital viral infection in the United States, and a major pathogen in solid organ and hematopoietic stem cell transplant recipients.CMV is transmitted via bodily fluids, sexual...
Myocarditis II: Clinical Features and Diagnostic Tests01:27

Myocarditis II: Clinical Features and Diagnostic Tests

Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autoantibody associations in patients with early diffuse cutaneous systemic sclerosis: the prospective registry of early systemic sclerosis.

Seminars in arthritis and rheumatism·2026
Same author

Second Report of the American Intestinal Transplant Working Group: New Insights Into Risk Factors, Treatment Regimens, and Outcomes of Malignancy After Intestinal Transplantation.

Transplantation·2026
Same author

Pediatric liver transplantation for metabolic diseases: a single-center experience.

World journal of pediatrics : WJP·2026
Same author

Discordance Between Patient and Physician Global Assessments in Early Systemic Sclerosis.

Arthritis care & research·2026
Same author

Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE.

The lancet. HIV·2026
Same author

Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.

Lancet (London, England)·2026
Same journal

Risk of Femoral Head Osteonecrosis Following Hip Trauma in Adults With Systemic Lupus Erythematosus.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study: Erratum.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Efficacy and Safety of Intravenous Golimumab in Ankylosing Spondylitis Patients With Early and Late Disease Through One Year of the GO-ALIVE Study: Erratum.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Microbiome Dysbiosis as a Potential Driver of Inflammatory Mimicry in Pachydermoperiostosis-associated Hypertrophic Osteoarthropathy.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Understanding Gaps in Methotrexate Education in the Adolescent and Young Adult Population.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
Same journal

Prevalence of Attention Deficit Hyperactivity Disorder in Adult Patients With Fibromyalgia.

Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases·2026
See all related articles

Related Experiment Video

Updated: Jun 17, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Voriconazole-associated myositis.

Victoria K Shanmugam1, Cal Matsumoto, Edward Pien

  • 1Division of Rheumatology, Immunology and Allergy, Georgetown University Hospital, Washington, DC 20007, USA. vks4@gunet.georgetown.edu

Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases
|December 17, 2009
PubMed
Summary
This summary is machine-generated.

Voriconazole, a common antifungal, can cause drug-induced myopathy, a rare side effect. This case highlights the importance of considering voriconazole-induced myopathy in transplant patients experiencing unexplained weakness.

Related Experiment Videos

Last Updated: Jun 17, 2026

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach
09:01

Vascular Occlusion Training for Inclusion Body Myositis: A Novel Therapeutic Approach

Published on: June 5, 2010

Area of Science:

  • Pharmacology
  • Neurology
  • Immunology

Background:

  • Voriconazole is a first-line antifungal for invasive aspergillosis.
  • Triazole antifungal agents are known to cause drug-induced myopathy.
  • This condition has not been previously reported with voriconazole.

Observation:

  • A 34-year-old renal transplant recipient developed severe generalized weakness.
  • The patient had a history of statin-induced myopathy.
  • Muscle enzymes were markedly elevated, and MRI showed inflammatory changes.

Findings:

  • Voriconazole treatment for invasive aspergillosis preceded the onset of symptoms.
  • Discontinuation of voriconazole led to symptom resolution and normalization of creatine kinase.
  • Magnetic resonance imaging revealed inflammatory changes consistent with myopathy.

Implications:

  • Voriconazole-induced myopathy is a potential adverse effect that should be considered.
  • Rheumatology consultants should include this in the differential diagnosis for weakness in transplant recipients.
  • Increased use of triazoles in immunocompromised patients necessitates awareness of this potential complication.